Worldwide we currently have more than 50 active alliances with biotech and pharmaceutical companies across all areas. Servier Australia is delighted that two key collaborations are with local centres of excellence:
Walter and Eliza Hall Institute of Medical Research (WEHI)
Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating several types of cancer, particularly blood cancers.
WEHI is the research powerhouse of the Victorian Comprehensive Cancer Centre, an alliance of leading Victorian hospitals and research centres committed to controlling cancer.
Researchers at WEHI, led by Associate Professor Guillaume Lessene, are working in collaboration with a team at the Alfred Hospital in Melbourne, to test the Servier compound – which targets proteins of the BCL2 family.
Early findings have been published in the journal Nature.
“Walter and Eliza Hall Institute researchers made the initial discovery explaining how BCL-2 played a role in cancer more than 20 years ago. MCL1, part of the BCL2 family, is important for many cancers because it is a pro-survival protein, that allows the cancerous cells to evade the process of programmed cell death which normally removes cancer cells from the body,” Associate Professor Lessene said.
The research was supported through a research collaboration with Servier and a number of other agencies.
Monash Institute of Pharmaceutical Sciences (MIPS)
The collaboration between Servier and MIPS makes use of world-leading capability in the identification of novel G Protein-Coupled Receptor (GPCR) targets and design of new chemical entities which modulate GPCR activity. GPCR represents the largest superfamily of all receptors (approximately 2% of the human genome) and are the targets for approximately 40% of modern medicines.)
MIPS is Australia’s leading faculty of pharmacy and pharmaceutical sciences, being at the forefront of both research and education in the field. Monash is ranked second in world university rankings for pharmacy and pharmacology for 2018; a repeat of 2017.
“We are excited to be working with leading Australian experts in GPCR research and to have the opportunity of being involved in the advancement and translation of GPCR-based research into new therapeutic agents for major human diseases.”
Professor Bill Charman Founding Director of MIPS, and Dean, Faculty of Pharmacy and Pharmaceutical Sciences.